ProCE Banner Activity

DESTINY-Breast01: Phase II Study of Trastuzumab Deruxtecan (DS-8201a) in HER2+ Advanced Breast Cancer Previously Treated With T-DM1

Slideset Download
Conference Coverage
In patients with HER2+ unresectable or metastatic breast cancer who were previously treated with T-DM1, trastuzumab deruxtecan achieved strong, durable benefit.

Released: December 18, 2019

Expiration: December 16, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen